Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 T-haNK, Bevacizumab and Randomized Phase 2b Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields with or without PD-L1 T-haNK in Participants with Recurrent or Progressive Glioblastoma
Not Available
II
Not Available
NCT06061809
VICC-DTNEU24006
A Phase 1/2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
Pancreatic
Pancreatic
Pancreatic
I/II
Cardin, Dana
NCT04172532
NCIGIP10366
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants with Relapsed or Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Multiple Cancer Types
Leukemia,
Myelodysplastic Syndrome
I
Ball, Somedeb
NCT06994676
VICCHEMP25017
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Multiple Cancer Types
Colon,
Rectal
II/III
Ciombor, Kristen
NCT05174169
SWOGGI008
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Multiple Cancer Types
Breast,
Gastrointestinal,
Gynecologic,
Head/Neck,
Lung,
Melanoma,
Neuro-Oncology,
Sarcoma,
Urologic
II
Choe, Jennifer
NCT05564377
VICC-NTMDT23238
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Multiple Cancer Types
The purpose of this study is to determine if the radiotracer, \[68Ga\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.
Breast,
Phase I
I
Rosenthal, Eben
NCT06828588
VICCBREP24601
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Breast
Breast
This phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor positive triple-negative breast carcinoma. Standard therapy before surgery for triple-negative breast cancer typically consists of a combination of chemotherapy and immunotherapy drugs. Chemotherapy drugs, such as carboplatin, paclitaxel, doxorubicin and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Giving darolutamide in combination with standard therapy before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.
Breast
II
Abramson, Vandana
NCT07016399
VICC-VCBRE23490
Promoting Self-Management in Head and Neck Cancer Survivors with Lymphedema and Fibrosis [PROMISE Trial]
Head/Neck
Head/Neck
Head/Neck
N/A
Murphy, Barbara
NCT06125743
VICC-EDHAN23569
A Phase 1, Open-Label Dose Escalation and Expansion Study of STX-0712 in Patients with Advanced Hematologic Malignancies
Leukemia
Leukemia
Leukemia
I
Ball, Somedeb
NCT06950034
VICCHEMP25067
Phase II Open-Label Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures
Head/Neck
Head/Neck
Head/Neck
II
Rosenthal, Eben
NCT04511078
VICCHN21109
